The Law Offices of Frank R. Cruz Announces Investigation of Instadose Pharma Corp. f/k/a Mikrocoze, Inc. (INSD) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Instadose Pharma Corp. f/k/a Mikrocoze, Inc.(“Instadose” or the “Company”) (OTC: INSD) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On November 23, 2021, the U.S. Securities and Exchange Commission (“SEC”) temporarily suspended trading of Instadose securities due to questions and concerns regarding the adequacy and accuracy of information about the company in the marketplace. The SEC specifically noted significant increases in the stock price and share volume unsupported by the company’s assets and financial information, trading that may be associated with individuals related to a control person of Instadose, and operations of Instadose’s Canadian affiliate.

On this news, once the Company’s trade suspension had ended, Instadose’s stock fell $22.61, or 91.87%, to close at $2.00 per share on December 9, 2021, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Instadose securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [e-mail], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.